|
- POLIVY® (polatuzumab vedotin-piiq) for certain types of Diffuse Large B . . .
POLIVY is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL)
- How does POLIVY® Work? | R R DLBCL Treatment
POLIVY (polatuzumab vedotin-piiq) is an FDA-approved treatment for adults with relapsed or refractory (R R) diffuse large B-cell lymphoma (DLBCL) who have already received at least 2 prior therapies
- POLIVY® Frequently Asked Questions | Certain Types of Newly Diagnosed . . .
Find answers to common questions about POLIVY® (polatuzumab vedotin-piiq) and certain types of newly diagnosed DLBCL See full safety information
- POLIVY Dosing and Administration Guide
POLIVY in combination with bendamustine and a rituximab product (BR) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), after at least 2 prior therapies
- How does POLIVY® Work?
POLIVY is designed to deliver the anti-cancer agent specifically to B cells, including cancerous B cells POLIVY (pronounced as “poh-LIH-vee”) is a type of targeted treatment made up of an antibody attached to an active anti-cancer agent (also known as an antibody-drug conjugate)
- What is Diffuse Large B-Cell Lymphoma? - polivy
For a sample list of questions to help you prepare for your next doctor's visit and understand your diagnosis and treatment options, including if POLIVY may be right for you, download this discussion guide
- POLIVY® (polatuzumab vedotin-piiq) for Diffuse Large B-Cell Lymphoma
Learn about POLIVY® (polatuzumab vedotin-piiq) plus R-CHP for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) See full safety information
- POLIVY + bendamustine + a rituximab product (BR) Dosing and . . .
POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least 2 prior therapies
|
|
|